News for Constellation Pharmaceuticals, Inc. (CNST)

**media[471316,471319]**

MorphoSys To Present New Phase 3 MANIFEST-2 Data on Pelabresib in Myelofibrosis in Oral Presentation at 2024 ASCO Annual Meeting

EQS-News: MorphoSys AG / Key word: Forecast MorphoSys Reports Preliminary 2023 Monjuvi U.S. Net Product Sales and Gross Margin, Provides 2024 Financial Guidance and Reduces...

MorphoSys shares have been climbing due to the approval chances of its lead candidate, pelabresib. Find out why I'm bullish on MOR stock.

Read trending news, stories and press releases from PMN Wire News about Canadian and international businesses.

EQS-News: MorphoSys AG / Key word: Miscellaneous MorphoSys to Host Virtual Investor Call with Key Opinion Leaders Focused on Pelabresib on June 21, 2023 14.06.2023 / 08:39... | June 14, 2023

Emma Reeve to support Editas’ evolution in new role as Chair of the Board Elliott Levy, M.D., joins Board as an Independent Director ...

EQS-News: MorphoSys AG / Key word: Miscellaneous MorphoSys Completes Enrollment of Phase 3 MANIFEST-2 Study of Pelabresib in Myelofibrosis with Topline Results Expected by End of 2023... | April 4, 2023

MorphoSys is a German commercial-stage biopharmaceutical company. See why we initiate with a HOLD rating on MOR stock.

Although headline inflation has slowed, the Fed will likely keep raising interest rates to attain its 2% target. However, a potential slowdown in monetary policy tightening is opening the path...

Amid rising global medical needs, the pharmaceutical industry is expected to witness robust growth in the coming years. Moreover, healthcare is considered relatively resilient amid market downturns. So, given the...

Gainers Allarity Therapeutics, Inc. (NASDAQ: ALLR) gained 240% to $0.90. Allarity Therapeutics, last month, posted a Q3 loss of $0.68 per share.